Role of FK506 binding proteins in neurodegenerative disorders

Current Medicinal Chemistry

Volumn 18, Issue 35, 2011, Pages 5380-5397

  Chattopadhaya, S ^a   Harikishore, A ^a   Yoon, H S ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

FK506 (Tacrolimus); FK506 binding proteins (FKBPs); Neurodegenerative disorders; Neuroimmunophilin ligand (NIL); PPIase activity

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; ALPHA SYNUCLEIN; COPPER ZINC SUPEROXIDE DISMUTASE; FK 506 BINDING PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCOCORTICOID; HEAT SHOCK PROTEIN 90; HUNTINGTIN; MICROTUBULE PROTEIN; N METHYL DEXTRO ASPARTIC ACID; NEUROIMMUNOPHILIN; NEUROMODULIN; NEUROTROPHIC FACTOR; NITRIC OXIDE SYNTHASE; POTASSIUM CHANNEL HERG; PROGESTERONE; PROTEIN TYROSINE KINASE; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CALCIUM HOMEOSTASIS; CELL MIGRATION; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; ISOMERIZATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; TETRATRICOPEPTIDE REPEAT; VISUAL CORTEX;

AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; FRONTOTEMPORAL DEMENTIA; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; TACROLIMUS BINDING PROTEINS;

EID: 82255169261     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798194441     Document Type: Article

References (184)

1. Uversky, V. N.; Oldfield, C. J.; Dunker, A. K., Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys, 2008, 37, 215-246.
2. Powers, E. T.; Morimoto, R. I.; Dillin, A.; Kelly, J. W.; Balch, W. E., Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem, 2009, 78, 959-991.
3. Tyedmers, J.; Mogk, A.; Bukau, B., Cellular strategies for controlling protein aggregation. Nat Rev Mol Cell Biol, 2010, 11, 777-788.
4. Rochet, J. C.; Lansbury, P. T., Jr., Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol, 2000, 10, 60-68. (Pubitemid 30099328)
5. Moore, D. J.; Dawson, V. L.; Dawson, T. M., Role for the ubiquitinproteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. Neuromolecular Med, 2003, 4, 95-108. (Pubitemid 37315188)
6. Dawson, T. M., Parkin and defective ubiquitination in Parkinson's disease. J Neural Transm Suppl, 2006, 70, 209-213. (Pubitemid 44622201)
7. Auluck, P. K.; Chan, H. Y.; Trojanowski, J. Q.; Lee, V. M.; Bonini, N. M., Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science, 2002, 295, 865-868. (Pubitemid 34118369)
8. Warrick, J. M.; Chan, H. Y.; Gray-Board, G. L.; Chai, Y.; Paulson, H. L.; Bonini, N. M., Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet, 1999, 23, 425-428.
9. Fernandez-Funez, P.; Nino-Rosales, M. L.; de Gouyon, B.; She, W. C.; Luchak, J. M.; Martinez, P.; Turiegano, E.; Benito, J.; Capovilla, M.; Skinner, P. J.; McCall, A.; Canal, I.; Orr, H. T.; Zoghbi, H. Y.; Botas, J., Identification of genes that modify ataxin-1-induced neurodegeneration. Nature, 2000, 408, 101-106.
10. Kazemi-Esfarjani, P.; Benzer, S., Genetic suppression of polyglutamine toxicity in Drosophila. Science, 2000, 287, 1837-1840. (Pubitemid 30143971)
11. Kampinga, H. H.; Craig, E. A., The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol, 2010, 11, 579-592.
12. Taipale, M.; Jarosz, D. F.; Lindquist, S., HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol, 2010, 515-528.
13. Sharkey, J.; Butcher, S. P., Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature, 1994, 371, 336-339. (Pubitemid 24300615)
14. Breiman, A.; Camus, I., The involvement of mammalian and plant FK506-binding proteins (FKBPs) in development. Transgenic Res, 2002, 11, 321-335. (Pubitemid 35301744)
15. Bharatham, N.; Chang, M. W.; Yoon, H. S., Targeting FK506 binding proteins to fight malarial and bacterial infections: current advances and future perspectives. Curr Med Chem, 2011, 18, 1874-1889.
16. Dornan, J.; Taylor, P.; Walkinshaw, M. D., Structures of immunophilins and their ligand complexes. Curr Top Med Chem, 2003, 3, 1392-1409.
17. Sabatini, D. M.; Lai, M. M.; Snyder, S. H., Neural roles of immunophilins and their ligands. Mol Neurobiol, 1997, 15, 223-239. (Pubitemid 127719579)
18. Barik, S., Immunophilins: for the love of proteins. Cell Mol Life Sci, 2006, 63, 2889-2900. (Pubitemid 46072296)
19. Sharma, V. K.; Li, B.; Khanna, A.; Sehajpal, P. K.; Suthanthiran, M., Which way for drug-mediated immunosuppression? Curr Opin Immunol, 1994, 6, 784-790. (Pubitemid 24312149)
20. Jinwal, U. K.; Koren, J., 3rd; Borysov, S. I.; Schmid, A. B.; Abisambra, J. F.; Blair, L. J.; Johnson, A. G.; Jones, J. R.; Shults, C. L.; O'Leary, J. C., 3rd; Jin, Y.; Buchner, J.; Cox, M. B.; Dickey, C. A., The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci, 2010, 30, 591-599.
21. Barth, S.; Nesper, J.; Hasgall, P. A.; Wirthner, R.; Nytko, K. J.; Edlich, F.; Katschinski, D. M.; Stiehl, D. P.; Wenger, R. H.; Camenisch, G., The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol, 2007, 27, 3758-3768. (Pubitemid 46726183)
22. Choi, B. H.; Feng, L.; Yoon, H. S., FKBP38 protects Bcl-2 from caspasedependent degradation. J Biol Chem, 2010, 285, 9770-9779.
23. Ahearn, I. M.; Tsai, F. D.; Court, H.; Zhou, M.; Jennings, B. C.; Ahmed, M.; Fehrenbacher, N.; Linder, M. E.; Philips, M. R., FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol Cell, 2011, 41, 173-185.
24. Shirane, M.; Nakayama, K. I., Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol, 2003, 5, 28-37. (Pubitemid 36054326)
25. Riggs, D. L.; Roberts, P. J.; Chirillo, S. C.; Cheung-Flynn, J.; Prapapanich, V.; Ratajczak, T.; Gaber, R.; Picard, D.; Smith, D. F., The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J, 2003, 22, 1158-1167. (Pubitemid 36313599)
26. Cameron, A. M.; Steiner, J. P.; Sabatini, D. M.; Kaplin, A. I.; Walensky, L. D.; Snyder, S. H., Immunophilin FK506 binding protein associated with inositol 1, 4, 5-trisphosphate receptor modulates calcium flux. Proc Natl Acad Sci U S A, 1995, 92, 1784-1788.
27. Wang, T.; Li, B. Y.; Danielson, P. D.; Shah, P. C.; Rockwell, S.; Lechleider, R. J.; Martin, J.; Manganaro, T.; Donahoe, P. K., The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell, 1996, 86, 435-444. (Pubitemid 26272083)
28. Jayaraman, T.; Brillantes, A. M.; Timerman, A. P.; Fleischer, S.; Erdjument-Bromage, H.; Tempst, P.; Marks, A. R., FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem, 1992, 267, 9474-9477.
29. Shim, S.; Yuan, J. P.; Kim, J. Y.; Zeng, W.; Huang, G.; Milshteyn, A.; Kern, D.; Muallem, S.; Ming, G. L.; Worley, P. F., Peptidyl-prolyl isomerase FKBP52 controls chemotropic guidance of neuronal growth cones via regulation of TRPC1 channel opening. Neuron, 2009, 64, 471-483.
30. Yang, W. M.; Inouye, C. J.; Seto, E., Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity. J Biol Chem, 1995, 270, 15187-15193.
31. Ochocka, A. M.; Kampanis, P.; Nicol, S.; Allende-Vega, N.; Cox, M.; Marcar, L.; Milne, D.; Fuller-Pace, F.; Meek, D., FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett, 2009, 583, 621-626.
32. Nelson, C. J.; Santos-Rosa, H.; Kouzarides, T., Proline isomerization of histone H3 regulates lysine methylation and gene expression. Cell, 2006, 126, 905-916. (Pubitemid 44310777)
33. Kuzuhara, T.; Horikoshi, M., A nuclear FK506-binding protein is a histone chaperone regulating rDNA silencing. Nat Struct Mol Biol, 2004, 11, 275-283. (Pubitemid 38282774)
34. Jin, Y. J.; Burakoff, S. J., The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. Proc Natl Acad Sci U S A, 1993, 90, 7769-7773. (Pubitemid 23250032)
35. Noguchi, J.; Ozawa, M.; Nakai, M.; Somfai, T.; Kikuchi, K.; Kaneko, H.; Kunieda, T., Affected homologous chromosome pairing and phosphorylation of testis specific histone, H2AX, in male meiosis under FKBP6 deficiency. J Reprod Dev, 2008, 54, 203-207. (Pubitemid 351918073)
36. Kumar, P.; Mark, P. J.; Ward, B. K.; Minchin, R. F.; Ratajczak, T., Estradiolregulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells. Biochem Biophys Res Commun, 2001, 284, 219-225. (Pubitemid 32924330)
37. Desmetz, C.; Bascoul-Mollevi, C.; Rochaix, P.; Lamy, P. J.; Kramar, A.; Rouanet, P.; Maudelonde, T.; Mange, A.; Solassol, J., Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res, 2009, 15, 4733-4741.
38. Pei, H.; Li, L.; Fridley, B. L.; Jenkins, G. D.; Kalari, K. R.; Lingle, W.; Petersen, G.; Lou, Z.; Wang, L., FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell, 2009, 16, 259-266.
39. Li, L.; Lou, Z.; Wang, L., The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer, 2011, 104, 19-23.
40. Gold, B. G., FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol, 1997, 15, 285-306. (Pubitemid 127720199)
41. Steiner, J. P.; Connolly, M. A.; Valentine, H. L.; Hamilton, G. S.; Dawson, T. M.; Hester, L.; Snyder, S. H., Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med, 1997, 3, 421-428. (Pubitemid 27145684)
42. Hamilton, G. S.; Huang, W.; Connolly, M. A.; Ross, D. T.; Guo, H.; Valentine, H. L.; Suzdak, P. D.; Steiner, J. P., FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of parkinson's disease. Bioorg Med Chem Lett, 1997, 7, 1785-1790. (Pubitemid 27321504)
43. Lyons, W. E.; George, E. B.; Dawson, T. M.; Steiner, J. P.; Snyder, S. H., Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A, 1994, 91, 3191-3195. (Pubitemid 24130201)
44. Snyder, S. H.; Sabatini, D. M., Immunophilins and the nervous system. Nat Med, 1995, 1, 32-37.
45. Tong, G.; Shepherd, D.; Jahr, C. E., Synaptic desensitization of NMDA receptors by calcineurin. Science, 1995, 267, 1510-1512.
46. Hodgkiss, J. P.; Kelly, J. S., Only 'de novo' long-term depression (LTD) in the rat hippocampus in vitro is blocked by the same low concentration of FK506 that blocks LTD in the visual cortex. Brain Res, 1995, 705, 241-246. (Pubitemid 26037369)
47. Funauchi, M.; Haruta, H.; Tsumoto, T., Effects of an inhibitor for calcium/calmodulin-dependent protein phosphatase, calcineurin, on induction of long-term potentiation in rat visual cortex. Neurosci Res, 1994, 19, 269-278. (Pubitemid 24146906)
48. Steiner, J. P.; Hamilton, G. S.; Ross, D. T.; Valentine, H. L.; Guo, H.; Connolly, M. A.; Liang, S.; Ramsey, C.; Li, J. H.; Huang, W.; Howorth, P.; Soni, R.; Fuller, M.; Sauer, H.; Nowotnik, A. C.; Suzdak, P. D., Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci U S A, 1997, 94, 2019-2024. (Pubitemid 27113954)
49. Gerlach, M.; Riederer, P.; Przuntek, H.; Youdim, M. B., MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol, 1991, 208, 273-286.
50. Sauer, H.; Francis, J. M.; Jiang, H.; Hamilton, G. S.; Steiner, J. P., Systemic treatment with GPI 1046 improves spatial memory and reverses cholinergic neuron atrophy in the medial septal nucleus of aged mice. Brain Res, 1999, 842, 109-118. (Pubitemid 29447858)
51. Dawson, T. M.; Steiner, J. P.; Lyons, W. E.; Fotuhi, M.; Blue, M.; Snyder, S. H., The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience, 1994, 62, 569-580.
52. Steiner, J. P.; Dawson, T. M.; Fotuhi, M.; Glatt, C. E.; Snowman, A. M.; Cohen, N.; Snyder, S. H., High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature, 1992, 358, 584-587.
53. Avramut, M.; Achim, C. L., Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem, 2003, 3, 1376-1382.
54. Charters, A. R.; Kobayashi, M.; Butcher, S. P., Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. Biochem Soc Trans, 1994, 22, 411S. (Pubitemid 24373130)
55. Coss, M. C.; Stephens, R. M.; Morrison, D. K.; Winterstein, D.; Smith, L. M.; Simek, S. L., The immunophilin FKBP65 forms an association with the serine/threonine kinase c-Raf-1. Cell Growth Differ, 1998, 9, 41-48. (Pubitemid 28049526)
56. Chambraud, B.; Belabes, H.; Fontaine-Lenoir, V.; Fellous, A.; Baulieu, E. E., The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEBJ, 2007, 21, 2787-2797. (Pubitemid 47372746)
57. Meiri, K. F.; Bickerstaff, L. E.; Schwob, J. E., Monoclonal antibodies show that kinase C phosphorylation of GAP-43 during axonogenesis is both spatially and temporally restricted in vivo. J Cell Biol, 1991, 112, 991-1005. (Pubitemid 21909644)
58. Snyder, S. H.; Lai, M. M.; Burnett, P. E., Immunophilins in the nervous system. Neuron, 1998, 21, 283-294. (Pubitemid 28399689)
59. Burnett, P. E.; Blackshaw, S.; Lai, M. M.; Qureshi, I. A.; Burnett, A. F.; Sabatini, D. M.; Snyder, S. H., Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. Proc Natl Acad Sci U S A, 1998, 95, 8351-8356. (Pubitemid 28326116)
60. Charng, M. J.; Kinnunen, P.; Hawker, J.; Brand, T.; Schneider, M. D., FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors. J Biol Chem, 1996, 271, 22941-22944. (Pubitemid 26314719)
61. Snyder, S. H., Nitric Oxide: first in a new class of neurotransmitters. Science, 1992, 257, 494-496.
62. Butcher, S. P.; Henshall, D. C.; Teramura, Y.; Iwasaki, K.; Sharkey, J., Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci, 1997, 17, 6939-6946. (Pubitemid 27427872)
63. Kantor, D. B.; Lanzrein, M.; Stary, S. J.; Sandoval, G. M.; Smith, W. B.; Sullivan, B. M.; Davidson, N.; Schuman, E. M., A role for endothelial NO synthase in LT P revealed by adenovirus-mediated inhibition and rescue. Science, 1996, 274, 1744-1748. (Pubitemid 26414913)
64. O'Dell, T. J.; Hawkins, R. D.; Kandel, E. R.; Arancio, O., Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci U S A, 1991, 88, 11285-11289. (Pubitemid 21916025)
65. Shibuki, K.; Okada, D., Endogenous nitric oxide release required for longterm synaptic depression in the cerebellum. Nature, 1991, 349, 326-328. (Pubitemid 21912074)
66. Malen, P. L.; Chapman, P. F., Nitric oxide facilitates long-term potentiation, but not long-term depression. J Neurosci, 1997, 17, 2645-2651. (Pubitemid 27137430)
67. Steiner, J. P.; Dawson, T. M.; Fotuhi, M.; Snyder, S. H., Immunophilin regulation of neurotransmitter release. Mol Med, 1996, 2, 325-333. (Pubitemid 26265082)
68. Nichols, R. A.; Suplick, G. R.; Brown, J. M., Calcineurin-mediated protein dephosphorylation in brain nerve terminals regulates the release of glutamate. J Biol Chem, 1994, 269, 23817-23823. (Pubitemid 24293593)
69. De Camilli, P.; Takei, K., Molecular mechanisms in synaptic vesicle endocytosis and recycling. Neuron, 1996, 16, 481-486. (Pubitemid 26101101)
70. Szep, S.; Park, S.; Boder, E. T.; Van Duyne, G. D.; Saven, J. G., Structural coupling between FKBP12 and buried water. Proteins, 2009, 74, 603-611.
71. Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J., Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science, 1991, 252, 839-842. (Pubitemid 121000524)
72. Fulton, K. F.; Jackson, S. E.; Buckle, A. M., Energetic and structural analysis of the role of tryptophan 59 in FKBP12. Biochemistry, 2003, 42, 2364-2372. (Pubitemid 36255210)
73. Maestre-Martinez, M.; Edlich, F.; Jarczowski, F.; Weiwad, M.; Fischer, G.; Lucke, C., Solution structure of the FK506-binding domain of human FKBP38. J Biomol NMR, 2006, 34, 197-202.
74. 2+/calmodulin. EMBO J, 2005, 24, 2688-2699. (Pubitemid 41076324)
75. 2+ target recognition activates the Bcl-2 regulator FKBP38. J Biol Chem, 2007, 282, 36496-36504.
76. Maestre-Martinez, M.; Haupt, K.; Edlich, F.; Neumann, P.; Parthier, C.; Stubbs, M. T.; Fischer, G.; Lucke, C., A charge-sensitive loop in the FKBP38 catalytic domain modulates Bcl-2 binding. J Mol Recognit, 2011, 24, 23-34.
77. Denny, W. B.; Valentine, D. L.; Reynolds, P. D.; Smith, D. F.; Scammell, J. G., Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology, 2000, 141, 4107-4113.
78. Reynolds, P. D.; Ruan, Y.; Smith, D. F.; Scammell, J. G., Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. J Clin Endocrinol Metab, 1999, 84, 663-669. (Pubitemid 29075703)
79. Wilson, K. P.; Yamashita, M. M.; Sintchak, M. D.; Rotstein, S. H.; Murcko, M. A.; Boger, J.; Thomson, J. A.; Fitzgibbon, M. J.; Black, J. R.; Navia, M. A., Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin. Acta Crystallogr D Biol Crystallogr, 1995, 51, 511-521.
80. Sanchez, E. R., Hsp56: a novel heat shock protein associated with untransformed steroid receptor complexes. J Biol Chem, 1990, 265, 22067-22070. (Pubitemid 120014264)
81. Silverstein, A. M.; Galigniana, M. D.; Kanelakis, K. C.; Radanyi, C.; Renoir, J. M.; Pratt, W. B., Different regions of the immunophilin FKBP52 determine its association with the glucocorticoid receptor, hsp90, and cytoplasmic dynein. J Biol Chem, 1999, 274, 36980-36986.
82. Wu, B.; Li, P.; Liu, Y.; Lou, Z.; Ding, Y.; Shu, C.; Ye, S.; Bartlam, M.; Shen, B.; Rao, Z., 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex. Proc Natl Acad Sci U S A, 2004, 101, 8348-8353. (Pubitemid 38736578)
83. Miyata, Y.; Chambraud, B.; Radanyi, C.; Leclerc, J.; Lebeau, M. C.; Renoir, J. M.; Shirai, R.; Catelli, M. G.; Yahara, I.; Baulieu, E. E., Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci U S A, 1997, 94, 14500-14505. (Pubitemid 28041403)
84. McGeer, P. L.; Itagaki, S.; Boyes, B. E.; McGeer, E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38, 1285-1291.
85. Nagatsu, T.; Sawada, M., Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des, 2005, 11, 999-1016. (Pubitemid 40331301)
86. Tong, Y.; Shen, J., alpha-synuclein and LRRK2: partners in crime. Neuron, 2009, 64, 771-773.
87. Mandel, S.; Grunblatt, E.; Riederer, P.; Amariglio, N.; Jacob-Hirsch, J.; Rechavi, G.; Youdim, M. B., Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci, 2005, 1053, 356-375. (Pubitemid 43031116)
88. Eriksen, J. L.; Wszolek, Z.; Petrucelli, L., Molecular pathogenesis of Parkinson disease. Arch Neurol, 2005, 62, 353-357. (Pubitemid 40349469)
89. Koga, H.; Cuervo, A. M., Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis, 2011, 43, 29-37.
90. Yang, Q.; She, H.; Gearing, M.; Colla, E.; Lee, M.; Shacka, J. J.; Mao, Z., Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science, 2009, 323, 124-127.
91. Goedert, M., Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci, 2001, 2, 492-501. (Pubitemid 33676584)
92. Ischiropoulos, H., Oxidative modifications of alpha-synuclein. Ann N Y Acad Sci, 2003, 991, 93-100.
93. Cookson, M. R., alpha-Synuclein and neuronal cell death. Mol Neurodegener, 2009, 4, 9.
94. Glass, C. K.; Saijo, K.; Winner, B.; Marchetto, M. C.; Gage, F. H., Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140, 918-934.
95. Kragh, C. L.; Lund, L. B.; Febbraro, F.; Hansen, H. D.; Gai, W. P.; El-Agnaf, O.; Richter-Landsberg, C.; Jensen, P. H., {alpha}-Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells. J Biol Chem, 2009, 284, 10211-10222.
96. Khandelwal, P. J.; Dumanis, S. B.; Feng, L. R.; Maguire-Zeiss, K.; Rebeck, G.; Lashuel, H. A.; Moussa, C. E., Parkinson-related parkin reduces alpha-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener, 2010, 5, 47.
97. Meuvis, J.; Gerard, M.; Desender, L.; Baekelandt, V.; Engelborghs, Y., The conformation and the aggregation kinetics of alpha-synuclein depend on the proline residues in its C-terminal region. Biochemistry, 2010, 49, 9345-9352.
98. Gerard, M.; Debyser, Z.; Desender, L.; Kahle, P. J.; Baert, J.; Baekelandt, V.; Engelborghs, Y., The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEBJ, 2006, 20, 524-526. (Pubitemid 46671237)
99. Gerard, M.; Deleersnijder, A.; Daniels, V.; Schreurs, S.; Munck, S.; Reumers, V.; Pottel, H.; Engelborghs, Y.; Van den Haute, C.; Taymans, J. M.; Debyser, Z.; Baekelandt, V., Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J Neurosci, 2010, 30, 2454-2463.
100. Gerard, M.; Debyser, Z.; Desender, L.; Baert, J.; Brandt, I.; Baekelandt, V.; Engelborghs, Y., FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T. J Neurochem, 2008, 106, 121-133. (Pubitemid 351840195)
101. Kopito, R. R., Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol, 2000, 10, 524-530.
102. Fusco, D.; Vargiolu, M.; Vidone, M.; Mariani, E.; Pennisi, L. F.; Bonora, E.; Capellari, S.; Dirnberger, D.; Baumeister, R.; Martinelli, P.; Romeo, G., The RET51/FKBP52 complex and its involvement in Parkinson disease. Hum Mol Genet, 2010, 19, 2804-2816.
103. Hurst, R. S.; Higdon, N. R.; Lawson, J. A.; Clark, M. A.; Rutherford-Root, K. L.; McDonald, W. G.; Haas, J. V.; McGrath, J. P.; Meglasson, M. D., Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol, 2003, 482, 31-37. (Pubitemid 37505924)
104. Wang, H. Q.; Nakaya, Y.; Du, Z.; Yamane, T.; Shirane, M.; Kudo, T.; Takeda, M.; Takebayashi, K.; Noda, Y.; Nakayama, K. I.; Nishimura, M., Interaction of presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2. Hum Mol Genet, 2005, 14, 1889-1902. (Pubitemid 41418059)
105. Walker, V. E.; Atanasiu, R.; Lam, H.; Shrier, A., Co-chaperone FKBP38 promotes HERG trafficking. J Biol Chem, 2007, 282, 23509-23516. (Pubitemid 47311946)
106. Gendron, T. F.; Petrucelli, L., The role of tau in neurodegeneration. Mol Neurodegener, 2009, 4, 13.
107. Ishizawa, T.; Mattila, P.; Davies, P.; Wang, D.; Dickson, D. W., Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol, 2003, 62, 389-397. (Pubitemid 36403039)
108. Muntane, G.; Dalfo, E.; Martinez, A.; Ferrer, I., Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alphasynucleinopathies. Neuroscience, 2008, 152, 913-923.
109. Giasson, B. I.; Forman, M. S.; Higuchi, M.; Golbe, L. I.; Graves, C. L.; Kotzbauer, P. T.; Trojanowski, J. Q.; Lee, V. M., Initiation and synergistic fibrillization of tau and alpha-synuclein. Science, 2003, 300, 636-640. (Pubitemid 36520587)
110. Jensen, P. H.; Hager, H.; Nielsen, M. S.; Hojrup, P.; Gliemann, J.; Jakes, R., alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem, 1999, 274, 25481-25489. (Pubitemid 29418572)
111. Duka, T.; Duka, V.; Joyce, J. N.; Sidhu, A., Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J, 2009, 23, 2820-2830.
112. Chambraud, B.; Sardin, E.; Giustiniani, J.; Dounane, O.; Schumacher, M.; Goedert, M.; Baulieu, E. E., A role for FKBP52 in Tau protein function. Proc Natl Acad Sci U S A, 2010, 107, 2658-2663.
113. McGeer, P. L.; McGeer, E. G., NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging, 2007, 28, 639-647. (Pubitemid 46349357)
114. Churcher, I., Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem, 2006, 6, 579-595.
115. Ballatore, C.; Lee, V. M.; Trojanowski, J. Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci, 2007, 8, 663-672. (Pubitemid 47283144)
116. Thal, D. R.; Holzer, M.; Rub, U.; Waldmann, G.; Gunzel, S.; Zedlick, D.; Schober, R., Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol, 2000, 163, 98-110. (Pubitemid 30314364)
117. Matus, S.; Glimcher, L. H.; Hetz, C., Protein folding stress in neurodegenerative diseases: a glimpse into the ER. Curr Opin Cell Biol, 2011, 23, 239-252.
118. Yoo, B. C.; Seidl, R.; Cairns, N.; Lubec, G., Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl, 1999, 57, 315-322.
119. Yang, Y.; Turner, R. S.; Gaut, J. R., The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Abeta40 and Abeta42 secretion. J Biol Chem, 1998, 273, 25552-25555. (Pubitemid 28475772)
120. Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; De Lucia, M.; McGowan, E.; Lewis, J.; Prihar, G.; Kim, J.; Dillmann, W. H.; Browne, S. E.; Hall, A.; Voellmy, R.; Tsuboi, Y.; Dawson, T. M.; Wolozin, B.; Hardy, J.; Hutton, M., CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet, 2004, 13, 703-714. (Pubitemid 38455958)
121. Kumar, P.; Ambasta, R. K.; Veereshwarayya, V.; Rosen, K. M.; Kosik, K. S.; Band, H.; Mestril, R.; Patterson, C.; Querfurth, H. W., CHIP and HSPs interact with beta-APP in a proteasome-dependent manner and influence Abeta metabolism. Hum Mol Genet, 2007, 16, 848-864. (Pubitemid 47061630)
122. Fonte, V.; Kipp, D. R.; Yerg, J., 3rd; Merin, D.; Forrestal, M.; Wagner, E.; Roberts, C. M.; Link, C. D., Suppression of in vivo beta-amyloid peptide toxicity by overexpression of the HSP-16.2 small chaperone protein. J Biol Chem, 2008, 283, 784-791.
123. Lim, J.; Lu, K. P., Pinning down phosphorylated tau and tauopathies. Biochim Biophys Acta, 2005, 1739, 311-322. (Pubitemid 40018547)
124. Pastorino, L.; Sun, A.; Lu, P. J.; Zhou, X. Z.; Balastik, M.; Finn, G.; Wulf, G.; Lim, J.; Li, S. H.; Li, X.; Xia, W.; Nicholson, L. K.; Lu, K. P., The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloidbeta production. Nature, 2006, 440, 528-534.
125. Salminen, A.; Ojala, J.; Kaarniranta, K.; Hiltunen, M.; Soininen, H., Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Prog Neurobiol, 2011, 93, 99-110.
126. Kraemer, B. C.; Burgess, J. K.; Chen, J. H.; Thomas, J. H.; Schellenberg, G. D., Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum Mol Genet, 2006, 15, 1483-1496.
127. Sugata, H.; Matsuo, K.; Nakagawa, T.; Takahashi, M.; Mukai, H.; Ono, Y.; Maeda, K.; Akiyama, H.; Kawamata, T., A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles. Neurosci Lett, 2009, 459, 96-99.
128. Liu, F. L.; Liu, P. H.; Shao, H. W.; Kung, F. L., The intracellular domain of amyloid precursor protein interacts with FKBP12. Biochem Biophys Res Commun, 2006, 350, 472-477.
129. Bezprozvanny, I.; Mattson, M. P., Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci, 2008, 31, 454-463.
130. Arispe, N.; Rojas, E.; Pollard, H. B., Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A, 1993, 90, 567-571. (Pubitemid 23028904)
131. Mark, R. J.; Pang, Z.; Geddes, J. W.; Uchida, K.; Mattson, M. P., Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci, 1997, 17, 1046-1054. (Pubitemid 27043963)
132. Zalk, R.; Lehnart, S. E.; Marks, A. R., Modulation of the ryanodine receptor and intracellular calcium. Annu Rev Biochem, 2007, 76, 367-385.
133. Lehnart, S. E.; Huang, F.; Marx, S. O.; Marks, A. R., Immunophilins and coupled gating of ryanodine receptors. Curr Top Med Chem, 2003, 3, 1383-1391.
134. Green, K. N.; Demuro, A.; Akbari, Y.; Hitt, B. D.; Smith, I. F.; Parker, I.; LaFerla, F. M., SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol, 2008, 181, 1107-1116. (Pubitemid 351915486)
135. Begley, J. G.; Duan, W.; Chan, S.; Duff, K.; Mattson, M. P., Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J Neurochem, 1999, 72, 1030-1039. (Pubitemid 29085017)
136. Schneider, I.; Reverse, D.; Dewachter, I.; Ris, L.; Caluwaerts, N.; Kuiperi, C.; Gilis, M.; Geerts, H.; Kretzschmar, H.; Godaux, E.; Moechars, D.; Van Leuven, F.; Herms, J., Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem, 2001, 276, 11539-11544.
137. Choi, B. H.; Yoon, H. S., FKBP38-Bcl-2 interaction: a novel link to chemoresistance. Curr Opin Pharmacol, 2011, 11, 354-359.
138. Sanokawa-Akakura, R.; Dai, H.; Akakura, S.; Weinstein, D.; Fajardo, J. E.; Lang, S. E.; Wadsworth, S.; Siekierka, J.; Birge, R. B., A novel role for the immunophilin FKBP52 in copper transport. J Biol Chem, 2004, 279, 27845-27848. (Pubitemid 38900051)
139. Hamza, I.; Faisst, A.; Prohaska, J.; Chen, J.; Gruss, P.; Gitlin, J. D., The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis. Proc Natl Acad Sci U S A, 2001, 98, 6848-6852. (Pubitemid 32538305)
140. Barnham, K. J.; Bush, A. I., Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol, 2008, 12, 222-228.
141. Sanokawa-Akakura, R.; Cao, W.; Allan, K.; Patel, K.; Ganesh, A.; Heiman, G.; Burke, R.; Kemp, F. W.; Bogden, J. D.; Camakaris, J.; Birge, R. B.; Konsolaki, M., Control of Alzheimer's amyloid beta toxicity by the high molecular weight immunophilin FKBP52 and copper homeostasis in Drosophila. PLoS One, 2010, 5, e8626.
142. Zoghbi, H. Y.; Orr, H. T., Glutamine repeats and neurodegeneration. Annu Rev Neurosci, 2000, 23, 217-247. (Pubitemid 30350043)
143. Green, H., Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell, 1993, 74, 955-956. (Pubitemid 23289453)
144. Perutz, M. F.; Johnson, T.; Suzuki, M.; Finch, J. T., Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A, 1994, 91, 5355-5358. (Pubitemid 24174325)
145. Bailey, C. K.; Andriola, I. F.; Kampinga, H. H.; Merry, D. E., Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet, 2002, 11, 515-523. (Pubitemid 34257488)
146. Landles, C.; Bates, G. P., Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep, 2004, 5, 958-963. (Pubitemid 39534452)
147. Sugars, K. L.; Rubinsztein, D. C., Transcriptional abnormalities in Huntington disease. Trends Genet, 2003, 19, 233-238. (Pubitemid 36511427)
148. Cha, J. H., Transcriptional dysregulation in Huntington's disease. Trends Neurosci, 2000, 23, 387-392.
149. Hay, D. G.; Sathasivam, K.; Tobaben, S.; Stahl, B.; Marber, M.; Mestril, R.; Mahal, A.; Smith, D. L.; Woodman, B.; Bates, G. P., Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet, 2004, 13, 1389-1405. (Pubitemid 38961645)
150. Ravikumar, B.; Rubinsztein, D. C., Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med, 2006, 27, 520-527. (Pubitemid 44466658)
151. Ravikumar, B.; Vacher, C.; Berger, Z.; Davies, J. E.; Luo, S.; Oroz, L.
152. Chiang, M. C.; Juo, C. G.; Chang, H. H.; Chen, H. M.; Yi, E. C.; Chern, Y., Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach. Mol Cell Proteomics, 2007, 6, 781-797. (Pubitemid 46831931)
153. Yamanaka, K.; Chun, S. J.; Boillee, S.; Fujimori-Tonou, N.; Yamashita, H.; Gutmann, D. H.; Takahashi, R.; Misawa, H.; Cleveland, D. W., Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci, 2008, 11, 251-253. (Pubitemid 351311795)
154. Manabe, Y.; Wang, J. M.; Murakami, T.; Warita, H.; Hayashi, T.; Shoji, M.; Abe, K., Expressions of nitrotyrosine and TUNEL immunoreactivities in cultured rat spinal cord neurons after exposure to glutamate, nitric oxide, or peroxynitrite. J Neurosci Res, 2001, 65, 371-377. (Pubitemid 32831388)
155. Warita, H.; Hayashi, T.; Murakami, T.; Manabe, Y.; Abe, K., Oxidative damage to mitochondrial DNA in spinal motoneurons of transgenic ALS mice. Brain Res Mol Brain Res, 2001, 89, 147-152. (Pubitemid 32322744)
156. Manabe, Y.; Warita, H.; Murakami, T.; Shiote, M.; Hayashi, T.; Omori, N.; Nagano, I.; Shoji, M.; Abe, K., Early decrease of the immunophilin FKBP 52 in the spinal cord of a transgenic model for amyotrophic lateral sclerosis. Brain Res, 2002, 935, 124-128. (Pubitemid 34327854)
157. Gold, B. G., Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs, 2000, 9, 2331-2342.
158. Armistead, D. M.; Badia, M. C.; Deininger, D. D.; Duffy, J. P.; Saunders, J. O.; Tung, R. D.; Thomson, J. A.; DeCenzo, M. T.; Futer, O.; Livingston, D. J.; Murcko, M. A.; Yamashita, M. M.; Navia, M. A., Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr D Biol Crystallogr, 1995, 51, 522-528.
159. Price, R. D.; Yamaji, T.; Yamamoto, H.; Higashi, Y.; Hanaoka, K.; Yamazaki, S.; Ishiye, M.; Aramori, I.; Matsuoka, N.; Mutoh, S.; Yanagihara, T.; Gold, B. G., FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action. Eur J Pharmacol, 2005, 509, 11-19. (Pubitemid 40248780)
160. Hamilton, G. S.; Steiner, J. P., Immunophilins: beyond immunosuppression. J Med Chem, 1998, 41, 5119-5143. (Pubitemid 29016306)
161. Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J., Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol, 1993, 229, 105-124. (Pubitemid 23037917)
162. Price, R. D.; Yamaji, T.; Matsuoka, N., FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway. Br J Pharmacol, 2003, 140, 825-829. (Pubitemid 37464063)
163. Wang, M. S.; Zeleny-Pooley, M.; Gold, B. G., Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. J Pharmacol Exp Ther, 1997, 282, 1084-1093. (Pubitemid 27340215)
164. Tanaka, K.; Ogawa, N., Possibility of non-immunosuppressive immunophilin ligands as potential therapeutic agents for Parkinson's disease. Curr Pharm Des, 2004, 10, 669-677. (Pubitemid 38292394)
165. Bavetta, S.; Hamlyn, P. J.; Burnstock, G.; Lieberman, A. R.; Anderson, P. N., The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol, 1999, 158, 382-393. (Pubitemid 29382828)
166. Kitamura, Y.; Itano, Y.; Kubo, T.; Nomura, Y., Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol, 1994, 50, 221-224. (Pubitemid 24071788)
167. Ross, D. T.; Guo, H.; Howorth, P.; Chen, Y.; Hamilton, G. S.; Steiner, J. P., The small molecule FKBP ligand GPI 1046 induces partial striatal reinnervation after intranigral 6-hydroxydopamine lesion in rats. Neurosci Lett, 2001, 297, 113-116.
168. Costantini, L. C.; Chaturvedi, P.; Armistead, D. M.; McCaffrey, P. G.; Deacon, T. W.; Isacson, O., A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol Dis, 1998, 5, 97-106. (Pubitemid 28430720)
169. Guo, X.; Dawson, V. L.; Dawson, T. M., Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci, 2001, 13, 1683-1693. (Pubitemid 32488058)
170. Winter, C.; Schenkel, J.; Burger, E.; Eickmeier, C.; Zimmermann, M.; Herdegen, T., The immunophilin ligand FK506, but not GPI-1046, protects against neuronal death and inhibits c-Jun. expression in the substantia nigra pars compacta following transection of the rat medial forebrain bundle. Neuroscience, 2000, 95, 753-762.
171. Parker, E. M.; Monopoli, A.; Ongini, E.; Lozza, G.; Babij, C. M., Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression. Neuropharmacology, 2000, 39, 1913-1919. (Pubitemid 30398495)
172. Christner, C.; Herdegen, T.; Fischer, G., FKBP ligands as novel therapeutics for neurological disorders. Mini Rev Med Chem, 2001, 1, 377-397.
173. Harper, S.; Bilsland, J.; Young, L.; Bristow, L.; Boyce, S.; Mason, G.; Rigby, M.; Hewson, L.; Smith, D.; O'Donnell, R.; O'Connor, D.; Hill, R. G.; Evans, D.; Swain, C.; Williams, B.; Hefti, F., Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience, 1999, 88, 257-267. (Pubitemid 28440407)
174. Pong, K.; Zaleska, M. M., Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord, 2003, 2, 349-356.
175. Emborg, M. E.; Shin, P.; Roitberg, B.; Sramek, J. G.; Chu, Y.; Stebbins, G. T.; Hamilton, J. S.; Suzdak, P. D.; Steiner, J. P.; Kordower, J. H., Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol, 2001, 168, 171-182. (Pubitemid 32195269)
176. Gold, B. G.; Armistead, D. M.; Wang, M. S., Non-FK506-binding protein-12 neuroimmunophilin ligands increase neurite elongation and accelerate nerve regeneration. J Neurosci Res, 2005, 80, 56-65. (Pubitemid 40577293)
177. Gold, B. G.; Densmore, V.; Shou, W.; Matzuk, M. M.; Gordon, H. S., Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther, 1999, 289, 1202-1210. (Pubitemid 29246645)
178. Edlich, F.; Weiwad, M.; Wildemann, D.; Jarczowski, F.; Kilka, S.; Moutty, M. C.; Jahreis, G.; Lucke, C.; Schmidt, W.; Striggow, F.; Fischer, G., The specific FKBP38 inhibitor N-(N', N'-dimethylcarboxamidomethyl) cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. J Biol Chem, 2006, 281, 14961-14970. (Pubitemid 43855200)
179. Ruan, B.; Pong, K.; Jow, F.; Bowlby, M.; Crozier, R. A.; Liu, D.; Liang, S.; Chen, Y.; Mercado, M. L.; Feng, X.; Bennett, F.; von Schack, D.; McDonald, L.; Zaleska, M. M.; Wood, A.; Reinhart, P. H.; Magolda, R. L.; Skotnicki, J.; Pangalos, M. N.; Koehn, F. E.; Carter, G. T.; Abou-Gharbia, M.; Graziani, E. I., Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A, 2008, 105, 33-38.
180. Revill, W. P.; Voda, J.; Reeves, C. R.; Chung, L.; Schirmer, A.; Ashley, G.; Carney, J. R.; Fardis, M.; Carreras, C. W.; Zhou, Y.; Feng, L.; Tucker, E.; Robinson, D.; Gold, B. G., Genetically engineered analogs of ascomycin for nerve regeneration. J Pharmacol Exp Ther, 2002, 302, 1278-1285. (Pubitemid 34920253)
181. Dumont, F. J.; Staruch, M. J.; Koprak, S. L.; Siekierka, J. J.; Lin, C. S.; Harrison, R.; Sewell, T.; Kindt, V. M.; Beattie, T. R.; Wyvratt, M.; et al., The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med, 1992, 176, 751-760.
182. Wilkinson, D. E.; Thomas, B. E.t.; Limburg, D. C.; Holmes, A.; Sauer, H.; Ross, D. T.; Soni, R.; Chen, Y.; Guo, H.; Howorth, P.; Valentine, H.; Spicer, D.; Fuller, M.; Steiner, J. P.; Hamilton, G. S.; Wu, Y. Q., Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecolic derivatives as FKBP12 ligands and their in vivo neuroprotective effects. Bioorg Med Chem, 2003, 11, 4815-4825. (Pubitemid 37230138)
183. Holt, D. A.; Luengo, J. I.; Yamashita, D. S.; Oh, H. J.; Konialian, A. L.; Yen, H. K.; Rozamus, L. W.; Brandt, M.; Bossard, M. J., Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12. Journal of the American Chemical Society, 1993, 115, 9925-9938.
184. Holt, D. A.; Konialian-Beck, A. L.; Oh, H.-J.; Yen, H.-K.; Rozamus, L. W.; Krog, A. J.; Erhard, K. F.; Ortiz, E.; Levy, M. A.; Brandt, M.; Bossard, M. J.; Luengo, J. I., Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors. Bioorg Med Chem Lett, 1994, 4, 315-320. (Pubitemid 24127127)